Targeting Myeloid-Specific Integrin α9β1 Improves Short and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis And Inflammation.

Conclusions: We provide genetic and pharmacologic evidence for the first time that targeting myeloid-specific integrin α9β1 improves short and long-term functional outcome in stroke models with preexisting comorbidities by limiting cerebral thrombosis and inflammation. PMID: 32195632 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32195632?dopt=Abstract

Source: Circulation Research - March 19, 2020 Category: Cardiology Authors: Dhanesha N, Jain M, Tripathi A, Doddapattar P, Chorawala M, Bathla G, Nayak MK, Ghatge M, Lentz SR, Kon S, Chauhan AK Tags: Circ Res Source Type: research